The increasing number of breast carcinoma in situ detected by screening procedures makes it imperative to develop improved markers to stratify the risk of invasive cancer. Telomerase is detectable in invasive cancer, but not in normal tissues. We have microdissected frozen tissue blocks containing both DCIS and invasive cancer to assay the telomerase activity of these two lesions. The 46 available cases of concurrent DCIS and invasive breast cancer resulted in 43 DCIS samples and 38 invasive cancer samples adequate for analysis. Seventy per cent of the DCIS and all invasive cancer samples tested had detectable telomerase activity. In addition, we analysed telomerase activity in ten cases of DCIS that were not associated with invasive cancer, and detected telomerase activity in seven (70%). Mixing experiments showed no evidence of telomerase inhibitors in telomerase negative samples. Furthermore, periductal in¯ammatory in®ltrates were shown to be a potential confounding source of telomerase activity. Since DCIS lesions appear to be heterogeneous with respect to telomerase activity, and telomerase activation appears to precede the development of invasive cancer, telomerase activity may be a useful adjunct in stratifying the risk of developing invasive breast cancer in patients with DCIS.
Introduction
The widespread implementation of mammographic screening has dramatically increased the detection of carcinoma in-situ, but management is problematic because we are currently unable to assess the risk of subsequent invasive cancer development. Therefore, the development of clinically useful biomarkers that can predict behavior of DCIS is imperative.
Telomerase is a ribonucleoprotein enzyme which is responsible for maintaining the length of telomeres. It is detectable in germ cells, tissues with rapid cellular turnover, immortal cell lines, and cancer cells, but undetectable in most normal dierentiated somatic tissues (Bacchetti and Counter, 1995; Greider and Blackburn, 1996; Shay, 1995; Wright and Shay, 1995) . Telomerase activity has been proposed as a potentially useful tumor marker in breast cancer, since it has been detected in most invasive breast cancers, but not in benign breast lesions, with the possible exception of some ®broadenomas (Kim et al., 1994; Meeker and Coey, 1997; Nelson, 1996; Shay and Bacchetti, 1997) . In several studies of primary invasive breast cancers, approximately 75 ± 95% of tumors demonstrate telomerase activity, while 5 ± 25% are telomerase-negative (Bednarek et al., 1997; Carey et al., 1998; Hiyama et al., 1996; Landberg et al., 1997; Nawaz et al., 1997) . Initial results suggested that smaller, lymph nodenegative tumors were more likely to be telomerasenegative than their larger, lymph node-positive counterparts (Hiyama et al., 1996; Kim et al., 1994) , and it was postulated that telomerase activity is acquired during tumor progression to metastasis (Hiyama et al., 1996) . More recently, some studies have found correlations between telomerase activity and stage, traditional prognostic indicators, and clinical outcome in invasive breast cancer (Clark et al., 1997; Hoos et al., 1998) . Other studies, however, failed to show a correlation between telomerase activity and prognostic factors or clinical outcome in breast cancer (Bednarek et al., 1997; Carey et al., 1998; Nawaz et al., 1997; Sugino et al., 1996; Tsao et al., 1997) and (Carey et al., in preparation, 1999) .
Telomerase activity is likely to be in some way important to cell survival during neoplastic progression, possibly by delaying cellular senescence sufficiently to allow the accumulation of the multiple genetic alterations required for the malignant phenotype (Chiu and Harley, 1997; Klingelhutz, 1997; Oshimura and Barrett, 1997; Smith and PereiraSmith, 1996) . It is not known, however, when in neoplastic progression this activation occurs. Previous reports have detected telomerase activity in anywhere form 60 ± 100% of ductal carcinoma in situ (DCIS) of the breast (Bednarek et al., 1997; Poremba et al., 1998; Tsao et al., 1997; Yashima et al., 1998) , but the studies have been limited by small sample sizes (n=5 ± 17). The large proportion of invasive breast cancers that are telomerase positive (Carey et al., 1998) also suggest that telomerase activation may occur in early stages of the disease. We have therefore focused our attention on ductal carcinoma in situ (DCIS), a preinvasive lesion of the breast, as a possible stage in carcinogenesis in which telomerase activation occurs. If a substantial subset of DCIS is indeed telomerase negative, telomerase activity may provide a very useful marker to stratify the risk of developing invasive cancer in the emerging population of women in whom screening procedures have detected this early lesion.
Detection of telomerase activity in clinical specimens currently depends on an enzymatic assay, requiring fresh or frozen tissue samples . Since frozen specimens of DCIS lesions are not readily available due to the diagnostic requirement of excluding invasive cancer, we have analysed samples of invasive breast cancers in which a signi®cant proportion of the tumor consists of preinvasive lesions. We have microdissected these specimens in order to analyse distinct areas of in situ and invasive ductal breast cancer separately, using adjacent H&E stained sections for orientation. We report here on the telomerase activity of very small microdissected tissue samples of concurrent DCIS and invasive breast cancers. We then corroborated these results by assaying telomerase activity in a small number of samples that contained no detectable invasive cancer, and could therefore be evaluated using larger samples of tumor tissue.
Results

Descriptive statistics of clinical parameters
The median age at surgery in 34 patients of known age was 50, with a range of 26 ± 90 years. Median size of the invasive cancer was 3.2 cm in 29 patients, with a range of 1.1 ± 10.0 cm. Median DNA Index of the invasive cancer tissue was 1.3 in 26 cases, with a range of 1.0 ± 3.0. the median S phase fraction of the invasive cancer tissue was 4.4% in 22 cases, with a range of 1.0 ± 28%. The histological grades of the DCIS tissue samples were I (n=3), II (n=17), III (n=14), and indeterminate (n=3).
Quantitation of tissue samples and sample preservation
Telomerase assays are usually standardized by total protein concentration of sample extracts . Pilot experiments revealed that protein content of microdissected tissue could not be reliably quanti®ed by standard protein assays due to small sample size (data not shown). Semiquantitative PCR ampli®cation of genomic DNA was performed to determine the number of cells present in the tissue extracts. The median number of genome equivalents (see Materials and methods) measured in 128 microdissected samples was 3 ml, with a range of 0.5 ± 18.3 ml. Of the samples containing 1 genome equivalent/ml or more, 30 of 64 DCIS samples (47%) and 38 of 64 invasive cancer samples (59%) had detectable telomerase activity (P40.5). DNA content was comparable in telomerase positive and telomerase negative samples in both DCIS and invasive cancer (Figure 1 ). All cases in which the microdissected invasive cancer samples were telomerase-negative had detectable telomerase in extracts prepared from whole sections (data not shown). This suggested either a lack of telomerase positive cells in the microdissected tissue or a loss of telomerase activity during microdissection of the cryosections in some samples.
In order to determine the quality of tissue preservation after microdissection, cellular 28S rRNA was measured by semiquantitative RT ± PCR. Fortythree of 64 DCIS samples (67%) and 38 of 64 invasive cancer samples (59%) had detectable 28S rRNA levels. Telomerase positive samples had higher 28S rRNA levels than telomerase negative samples (P50.001) (see Figure 1 ), and semiquantitative telomerase activity correlated with rRNA levels (P50.02, data not shown). None of the samples lacking detectable 28S rRNA levels had telomerase activity. While several telomerase negative DCIS samples had detectable 28s rRNA levels, none of the telomerase negative invasive cancer samples had detectable 28s rRNA levels (see Figure 1 ).
Assessment of telomerase status in DCIS and invasive cancer samples
Based on these data, the analysis of telomerase activity was limited to samples with detectable levels of 28S rRNA in order to minimize the eects of tissue Figure 2 and Table 1 ).
In order to determine if telomerase activity was higher in invasive breast cancer than in DCIS lesions with detectable telomerase activity, we quanti®ed telomerase in a subset of patients in which sucient tissue was available for two independent samples each of DCIS and invasive cancer using the TRAPeze TM assay . The 11 cases in which both DCIS and cancer tissue showed detectable telomerase activity are shown in Figure 3 . For samples in which telomerase was detectable, no signi®cant dierence in telomerase activity was seen between paired DCIS and invasive cancer samples.
An additional cohort of ten cases from which a tissue block with pure DCIS was available was analysed to validate our results in the microdissection study using samples obtained from whole tissue sections. Assaying 0.1 mg and 1 mg aliquots of DCIS lysate eight of ten samples were telomerase-positive (data not shown). Histological review of these cases, however, showed periductal in¯ammatory in®ltrates in two of the telomerase-positive DCIS samples (see Figure 4) . To investigate the possible contribution to these in®ltrates to the detected telomerase activity, all tissue blocks without invasive breast cancer underwent microdissection as well. A separate interstitial sample without ductal tissue was obtained from the two cases of DCIS with periductal in®ltrates. The two negative DCIS cases remained negative, while seven of the eight positive DCIS cases were again positive. As shown in Figure 4 , the interstitial in®ltrates appeared to be the only source of telomerase activity in one of the two cases with periductal in¯ammation (Figure 4 , #5), while telomerase activity was detectable in both interstitial and ductal samples in the other (Figure 4 , #2).
Mixing experiments using equal amounts of telomerase-negative samples and telomerase-positive control extracts did not inhibit telomerase activity, ruling out tissue inhibitors of telomerase activity as a cause of false-negative assay results (data not shown).
Correlation of semiquantitative telomerase activity with tumor parameters
Where the information was available, possible correlations between telomerase activity and parameters such as patient age at surgery, overall tumor size, DNA index and S phase fraction of the breast cancer, and histological grade of the DCIS were examined by nonparametric testing using the Spearman rank correlations (see Table 2 ). The cohort of ten pure DCIS cases was not included in this analysis. A strong positive correlation was found between telomerase activity and patient age at surgery for DCIS samples (P=0.01) and, to a lesser degree, for invasive cancer tissue (P=0.07). Cancer size correlated positively with telomerase activity in the cancer tissue (P=0.05), but not in the DCIS samples (P=0.09). DNA index of the cancer tissue correlated with telomerase activity in both DCIS and cancer tissues (P=0.02). The S phase fraction of the cancer tissue did not correlate with telomerase activity (P40.1), although it was closely linked to cancer size (P=0.01) and histological grade of DCIS (P50.0001).
Discussion
In this study, we examined telomerase activity in DCIS adjacent to invasive breast cancer using microdissection to allow selective tissue sampling. We found that 30 of 43 DCIS samples (70%) and all 38 invasive cancer samples had detectable telomerase activity ( Figure 2 and Table 1 ). Similarly, three out of ten cases of DCIS that were not adjacent to invasive cancer lacked detectable telomerase. These results suggest that telomerase activity may be a useful biomarker for the development of invasive breast cancer in patients with DCIS, warranting a more extensive prospective study.
Unfortunately, the un®xed tissue currently required for the detection of telomerase activity is only rarely available from this type of lesion, since the surgical (B) buer control without added extract. MCF7 cell extracts (+C) and the TSR8 control template (T) served as positive controls. All assays contained 10 attograms of an internal telomerase assay standard (arrow, IC) for identi®cation of Taq polymerase inhibitors. Reaction products were electrophoresed in a 10% nondenaturing polyacrylamide gel and visualized using a Molecular Dynamics Phosphorimager screen Bednarek et al. (1997) reported on six DCIS tumors, all of which showed telomerase activity, Tsao et al. (1997) reported that nine out of 12 DCIS were telomerase positive. Yashima et al. (1998) reported that 11 out of 12 DCIS cases were telomerase positive, while Poremba et al. (1998) reported ten out of 17 positive cases.
A somewhat more readily available source of DCIS tissue are frozen tissue blocks from invasive breast cancers that also contain foci of DCIS, keeping in mind that this may systematically select DCIS lesions that may be more advanced than DCIS lesions found in women without evidence of invasive breast cancer. These tissue blocks formed the basis of our investigation. This approach necessitated selective sampling of the DCIS foci surrounding cancer tissue by microdissection techniques (Zhuang et al., 1995a) , which have been shown to allow selective analyses of dierent DCIS foci and genetically heterogeneous invasive cancer samples from the same tumor (Fujii et al., 1996; Zhuang et al., 1995b) . Unlike studies of various genetic markers, the tissue had to be dissected without ®xation or staining to avoid inactivating telomerase activity (data not shown). Appropriate sampling was subsequently con®rmed by reviewing the sections after H&E staining.
A number of technical issues had to be addressed for this study. False negative results due to insucient sampling was controlled for by measuring the amount of genomic DNA present. Tissue degradation during thawing and microdissection occurred in some samples since telomerase-negative microdissected cancer samples were telomerase-positive when assayed by standard methods using extracts from whole cryosections. Since RNA is considerably more labile than DNA, we used it to monitor tissue preservation. The content of 28S rRNA, a housekeeping gene which is expressed at constant levels in various tissues (Laborda, 1991) , was assessed by RT ± PCR. Since there was an excellent correlation between detectable 28S rRNA and telomerase activity (see Figure 1) , and invasive tumor samples lacking rRNA and telomerase activity could be shown to have detectable telomerase activity by standard methods, we excluded microdissected samples with no detectable 28S rRNA from this analysis. Since all telomerase-negative DCIS samples had both detectable telomerase activity in adjacent invasive cancer samples Figure 3 Comparison of telomerase activity in DCIS and invasive breast cancer samples from the same tissue block. Telomerase activity was measured by TRAPeze 1 assay in a subset of cases in which sucient tissue was available for two independent samples of DCIS and invasive cancer. The average telomerase values (corrected for rRNA content) of the 11 cases in which both DCIS and cancer tissue showed detectable telomerase activity are shown in (a). The similar distribution of the telomerase activity in these DCIS and cancer tissue samples is shown in (b) and had detectable rRNA, we are con®dent that our results re¯ect telomerase activity in the DCIS tissue closely.
Other causes of false negative results include PCR inhibition, which was monitored by the internal telomerase assay standard (ITAS), as well as tissue inhibitors, which currently can only be detected by mixing experiments and for which the microdissected samples were insucient. Mixing experiments were performed with telomerase-negative extracts from the small cohort of cases without invasive cancer, and no inhibitors were detected (data not shown).
False positive results due to contaminating telomerase activity from adjacent tissue can be minimized to some extent by careful microdissection techniques. We have previously reported that the interstitial in®ltrates often present in high grade DCIS with comedonecrosis can be a confounding source of telomerase activity (Umbricht et al., 1997) . Indeed, one telomerase-positive DCIS whole-section tissue sample was negative by microdissection, and the periductal in¯ammation was telomerase-positive (see Figure 4) . In¯ammatory in®ltrates as source of telomerase will require increased scrutiny, particularly in studies investigating the signi®cance of quantitative telomerase measurements in clinical material.
Since our microdissected DCIS samples come from patients with invasive breast cancers, they probably represent a late stage of DCIS. Similarly, the cohort of pure DCIS cases do not represent the typical DCIS lesion detected by mammography today, since the average size of these DCIS was 2.9 cm, and smaller lesions may well be more frequently telomerasenegative. Nevertheless, almost a third of our DCIS samples were telomerase-negative, whereas all invasive cancer samples were telomerase-positive. Thus, telomerase activation may indeed be occurring in DCIS, since invasive breast cancer is usually telomerase positive even in early stages (Carey et al., 1998) , and limited data on atypical hyperplasia (Poremba et al., 1998) suggest that earlier lesions are telomerase negative. While the source of low but detectable levels of telomerase in ®broadenomas (Hiyama et al., 1996; Poremba et al., 1998) will need to be investigated further, these lesions do not generally pose diagnostic diculties.
The previously reported correlation between telomerase and biological parameters such as patients age, tumor size, and DNA index (Clark et al., 1997) was again seen in the samples for which a quantitative assay was available. Telomerase activity was not signi®cantly higher in invasive cancer tissue than in DCIS if telomerase negative samples were excluded. This suggests that once telomerase activity reaches a threshold level, e.g. sucient to maintain telomeres, there is no selective advantage to increasing expression further. Also, the correlation between telomerase and DNA index (a measure of aneuploidy) and the lack of correlation with the S phase fraction (a measure of proliferation) suggests that telomerase is more than a simple proliferative index, although a relationship with proliferative indices has been detected in larger series (Clark et al., 1997) (Carey et al., in preparation, 1999) . Figure 4 Telomerase activity of periductal in®ltrates vs DCIS. TRAPeze 1 assays of microdissected tissue samples of DCIS cases (1 ± 6) without invasive cancer. Two ml of extract was used in each assay. Lanes (2) and (5) indicate lysates of periductal interstitial in®ltrates. Lanes 4* and 6* indicate DCIS samples that were telomerase-negative when whole section lysates were assayed. (Bu) buer control without added extract. All assays contained 10 attograms of an internal telomerase assay standard (arrow, IC) for identi®cation of Taq polymerase inhibitors. The tissue source of lanes 2 and 5 is illustrated at the top Materials and methods) . DCIS grade is the grade assigned by the pathologist (ME Sherman) to the DCIS sample analysed. Ca Size indicates maximal diameter of invasive cancer documented in the pathology report. Ca-DNA index is a measure of celluar aneuploidy in the invasive cancer. S phase denotes proportion of invasive cancer cells in S phase as determined at the time of surgery, and is a measure of cellular proliferation
No clinical outcome data were available for this study, so potential prognostic signi®cance of telomerase could not be addressed. The similar levels of telomerase activity seen in matched DCIS and cancer tissue (Figure 3 ) and the possible lack of prognostic implications of telomerase activity in early stages of invasive breast cancer (Carey et al., in preparation, 1999) suggest little bene®t to the cancer cell in overexpressing telomerase beyond what is necessary for telomerase maintenance, at least initially. This may not be the case in later stages of the disease, if high telomerase activity are associated with signi®cantly poorer outcomes in node-positive breast cancer (Clark et al., 1997) . These data could be explained be a progressive perturbation of regulatory processes during cancer progression, such that reactivated telomerase activity would only initially be maintained at a level matching cellular needs. Alternatively, and perhaps concurrently, very high telomerase activity in late stages may point to additional functions of telomerase beyond telomerase maintenance, such an increasing role in healing double-stranded DNA breaks as required by an ever-rising chromosomal instability often seen in solid tumors (Bednenko et al., 1997; Flint et al., 1994; Greider, 1994; Melek and Shippen, 1996) .
A growing body of evidence suggests the telomerase plays an important role in cancer biology (Shay and Bacchetti, 1997) . Since even in this series of late stage DCIS a signi®cant subset lacked telomerase activity, DCIS may in fact be a stage in tumor progression in which telomerase activation begins to confer a selective advantage to malignant cell populations. Since natural history studies of DCIS suggest that a subset of these tumors never develop invasive potential (Page et al., 1998) , it is tempting to speculate that telomerase activation contributes to this divergence within the natural history of DCIS lesions. Furthermore, telomerase may prove to be a valuable prognostic marker for the development of invasive cancer in patients with DCIS.
Materials and methods
Tissue samples
Two hundred and ®fteen cases of concurrent DCIS and invasive breast cancer were identi®ed in the Johns Hopkins tumor bank records from a ten year period. When available, the information on patient age at surgery, tumor size, DNA index, and histological grade of DCIS component was recorded. Consecutive 8 mm cryostat sections were obtained and the presence of invasive breast cancer and a 410% DCIS component was histological con®rmed in a total of 46 retrieved tissue blocks. An unstained section was brie¯y thawed and microdissected with a 22 g needle at low power magni®cation (1006) (Zhuang et al., 1995a) . Samples of 50 ± 100 cells of DCIS and invasive cancer tissue were collected separately and lysed in 15 ml telomerase lysis buer (Piatyszek et al., 1995) . After incubation for 30 min on ice, the lysates were centrifuged at 16 000 g for 10 min at 48C, 10 ml lysate was decanted, frozen in liquid N 2 and stored at 7808C. The remaining 5 ml were digested 624 h at 378C with 1 mg/ml Proteinase K (Boehringer) followed by heat inactivation at 958C 610' and stored at 7808C.
Additionally, 17 cases with tumor blocks containing DCIS without invasive breast cancer were identi®ed in the Duke University Hospital tumor bank records. Five cryostat sections were prepared as described above. DCIS was histologically con®rmed on H&E sections in the retrieved tissue blocks in 10 of 17 samples. Four of these cases also had invasive breast cancer in the contralateral breast or in noncontiguous tissue blocks. The other blocks showed invasive cancer (1), atypical hyperplasia (3), benign tumor (2), and one normal breast tissue, and were excluded from the analysis. The median DCIS size was 2.9 cm (range, 1 ± 10 cm). Two cryosections were used for extract preparation by overlaying the frozen sections with 50 ml telomerase lysis buer and aspirating the resulting lysates. The two other sections were used for microdissections as described above.
Quantitation of tissue sample by PCR assay of DNA content
While the whole section extracts were standardized by protein content as measured by Biorad 1 assay (Bradford, 1976) , protein was undetectable in the microdissected samples. In order to measure the amount of tissue present in the microdissected tissue extracts, PCR ampli®cation of genomic DNA was performed in the tissue extracts and in serial dilutions of MCF7 cell extracts (Hay et al., 1994) assayed in parallel. A 175 bp fragment of the human acidic ribosomal phosphoprotein PO gene (36D4, Genbank accession number M17885) (Laborda, 1991) was ampli®ed using the oligonucleotide primers 5'-GAT TGG CTA CCC AAC TGT TGCA (36B4FW) and 5'-CAGGGGCAGCAGCCACAAAGGC (36B4RV). The 36B4FW primer was end-labeled using T4 kinase (Boehringer) and 32 P-g-ATP . 25 ml PCR reactions were performed with Taq DNA polymerase (Perkin Elmer) on 2 ml of proteinase K treated tissue extract using assay conditions recommended by the manufacturer. The samples underwent the following thermal cycling protocol: 948C65 min, (558C645 s, 728C645 s, 948C630 s) 630 cycles. PCR products were separated in a 10% nondenaturing polyacrylamide gel in 0.56TBE buer (Sambrook et al., 1989) and imaged by phosphorimager screen (Molecular Dynamics). PCR product bands were measured by densitometry using the IPLabGel 1 program (Signal Analytics, Vienna, VA, USA) on a Macintosh microcomputer. Quantitation was performed after subtracting lane backgrounds from the genomic 36B4 signal ( Figure  5 ). The densitometric values of the bands were divided by an average per-cell value derived from the serial dilutions of Figure 5 Quantitation of tissue samples by PCR assay of DNA content. PCR reaction products were separated in a 10% nondenaturing polyacrylamide gel and imaged by phosphorimager screen, as shown in the upper panel. Densitometry of the product bands is illustrated in the lower panel. Quantitation was performed after lane backgrounds were subtracted by sampling identical segments above the product bands. These values were divided by an average per cell value derived from serial dilutions of MCF7 cell extracts run in parallel, and expressed in genome equivalents. p36B4 is a plasmid containing the 36B4 cDNA MCF7 cell extracts run in parallel, and expressed in genome equivalents.
Assessment of tissue sample preservation by RT ± PCR of RNA content RNA content in the tissue extracts was quantitated by RT ± PCR ampli®cation of a 28S rRNA fragment of 91 nucleotides (Genbank accession number M11167, bases 322 ± 413) using the oligonucleotide primers 5'-GCT AAA TAC CGG CAC GAG ACC GAT AG (28F1) and 5'-GGT TTC ACG CCC TCT TGA ACT CTC TC (28R1). Two ml of proteinase K treated tissue extract was used in a 25 ml reaction containing 2.5 mM manganese acetate, 50 mM bicine pH 8.2, 115 mM potassium acetate, 8% glycerol, 300 mM dNTP, 1.5 mM of both primers, 2.5 U of Tth DNA polymerase (Perkin Elmer), and 0.2 mg of an internal control RNA template, rRNA-IC. rRNA-IC is an in vitro RNA transcript of 72 bp in length that is ampli®ed by the 28F1/28R1 primer set. The 28S rRNA reaction mixture was placed in a thermal cycler block and underwent the following thermal cycling protocol: 948C66 min, 658C630 min, 948C690 s, (658C61 min, 948C630 s) 612 cycles, 608C67 min. The reaction products were separated on 12.5% nondenaturing polyacrylamide gel in 16TBE buer (Sambrook et al., 1989) and stained with SYBR TM -Green I (Molecular Probes Inc., Eugene, OR, USA) following the manufacturer's instructions, and the results analysed by¯uorescent densitometry using a Gel Print 2000I TM (BioPhotonics). To correct for variations in PT ± PCR eciency, quantitation of 28S rRNA was performed by dividing the¯uorescent signal from the sample lane by the signal from the competitive internal control (28S-IC). This quantity (28S rRNA/28S-IC) was then compared to the¯uorescent signal from dilutions of extracts of HeLa cells (Hay et al., 1994) or MCF7 cells ranging from 10 to 10 000 cells which were used to create a standard curve. Fluorescent signals were expressed in cell-equivalents (see Figure 6 ).
Telomerase assay
A 2 ml aliquot of extract was used for the telomerase assays. Standard telomere repeat ampli®cation protocol (TRAP) assays using TS and CX primers were performed as described (Piatyszek et al., 1995) . All assays contained 10 ag of the internal telomerase assay standard (ITAS) for identi®cation of Taq polymerase inhibitors. A paired sample was inactivated by preincubation with RNAse A (Boehringer Mannhein, Indianapolis, IN, USA). MCF7 cell extracts and the TSR8 control template served as positive control. For quantitation of telomerase activity, a modi®cation of the assay using the TRAPeze 1 kit (Oncor) was used instead. PCR products were electrophoresed in a 10% nondenaturing polyacrylamide gel in 0.56TBE buer (Sambrook et al., 1989) . The DNA ladders were visualized using a Molecular Dynamics Phosphorimager (see Figure 2) . Densitometry was performed with the IPLabGel 1 program (Signal Analytics, Vienna, VA, USA) on a Macintosh microcomputer.
Statistical analysis
All P values refer to either Fisher's Exact test for tables or Wilcoxon's Rank Sum test for nonparametric data, where appropriate. Correlations where analysed by Spearman's rank-order test. The analyses were performed using the JMP statistical software package (SAS Institute, Inc., Cary, NC, USA) on a Macintosh microcomputer. The cohort of ten cases with tissue blocks containing DCIS only was not included in the statistical analyses of the microdissection study.
Abbreviations DCIS, Ductal carcinoma in situ; TRAP, telomerase repeat ampli®cation protocol; TLB, Telomerase lysis buer; ag, attogram; PCR polymerase chain reaction; IC, internal control; RT ± PCR, reverse transcriptase ± PCR. Figure 6 Assessment of tissue sample preservation of RT ± PCR assay of 28S rRNA content. The RT ± PCR reaction products were separated on a 12.5% nondenaturing polyacrylamide gel, stained with SYBR TM -Green I, and analysed by¯uorescent densitometry (see Materials and methods). Quantitation was performed by dividing the¯uorescent signal from the sample lane (arrow, 28S rRNA) by signal from the 28S rRNA competitive internal control (arrow, IC) to correct for variations in RT ± PCR eciency. This quantity (28S rRNA/IC) was then compared to the¯uorescent signal from extracts of 10, 100, and 1000 MCF7 cells which were used to create a standard curve (three left lanes). (B) indicates a buer control lane without added extract. Fluorescent signals were expressed in cell-equivalents as indicated below the gel
